Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Everardo D Saad

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
The Indian Journal of Medical Research|November 18, 2011
Endpoints in advanced breast cancer: methodological aspects & clinical implicationsEverardo D Saad
Clinical Trials (London, England)|July 16, 2020
Commentary on Bamat et alEverardo D Saad, Marc Buyse
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 9, 2003
Targeted drugs in oncology: new names, new mechanisms, new paradigmWilliam Rotea, Everardo D Saad
Acta Oncologica (Stockholm, Sweden)|September 15, 2012
Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspectsEverardo D Saad, Marc Buyse
Journal of the National Cancer Institute|February 24, 2025
Noninferiority trials in oncology: need for improvement, or a paradigm shift?Marc Buyse, Everardo D Saad
Current Opinion in Oncology|June 17, 2020
Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpointsEverardo D Saad, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
CALGB 9633: an underpowered trial with a methodologically questionable conclusionArtur Katz, Everardo D Saad
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?Everardo D Saad, Marc Buyse
European Heart Journal. Acute Cardiovascular Care|February 8, 2024
Rethinking survival analysis: advancing beyond the hazard ratio?Johan Verbeeck, Everardo D Saad
Annals of Palliative Medicine|February 18, 2017
Assessment of quality of life in phase III trials of radiotherapy in localized or locally advanced head and neck cancer over the past 17 yearsGustavo Nader Marta, Everardo D Saad
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
The Indian Journal of Medical Research|November 18, 2011
Endpoints in advanced breast cancer: methodological aspects & clinical implicationsEverardo D Saad
Clinical Trials (London, England)|July 16, 2020
Commentary on Bamat et alEverardo D Saad, Marc Buyse
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 9, 2003
Targeted drugs in oncology: new names, new mechanisms, new paradigmWilliam Rotea, Everardo D Saad
Acta Oncologica (Stockholm, Sweden)|September 15, 2012
Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspectsEverardo D Saad, Marc Buyse
Journal of the National Cancer Institute|February 24, 2025
Noninferiority trials in oncology: need for improvement, or a paradigm shift?Marc Buyse, Everardo D Saad
Current Opinion in Oncology|June 17, 2020
Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpointsEverardo D Saad, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
CALGB 9633: an underpowered trial with a methodologically questionable conclusionArtur Katz, Everardo D Saad
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?Everardo D Saad, Marc Buyse
European Heart Journal. Acute Cardiovascular Care|February 8, 2024
Rethinking survival analysis: advancing beyond the hazard ratio?Johan Verbeeck, Everardo D Saad
Annals of Palliative Medicine|February 18, 2017
Assessment of quality of life in phase III trials of radiotherapy in localized or locally advanced head and neck cancer over the past 17 yearsGustavo Nader Marta, Everardo D Saad
Pageof 8